

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method for treating a disease condition cancer in a mammal human, the method comprising:

administering at least one vaccination of dendritic cells (DCs) to said mammal a human diagnosed as having a cancer; and

administering a cyclooxygenase (COX)-2 inhibiting compound inhibitor to said mammal human to enhance the effect of said at least one vaccination of DCs.

2. (Original) The method of claim 1, wherein each of said at least one vaccination of DC comprises from about 10^5 to about 10^7 DC.

3. (Currently amended) The method of claim 1, wherein administering said COX-2 inhibiting compound further inhibitor comprises administering said COX-2 inhibiting compound inhibitor in a dose of from about 0.1 to about 10,000 mg per day.

4. (Currently amended) The method of claim 1, wherein administering said COX-2 inhibiting compound further inhibitor comprises administering said COX-2 inhibiting compound inhibitor in a dose of from about 1.0 to about 1,000 mg per day.

5. (Currently amended) The method of claim 1, wherein said COX-2 inhibiting compound inhibitor is NS-398.

6. (Currently amended) The method of claim 1, wherein the ~~disease condition~~ cancer is selected from the group consisting of lung cancer, bladder cancer, colorectal cancer, and brain cancer.

7. (Currently amended) The method of claim 1, wherein said ~~disease condition~~ cancer is selected from the group consisting of ~~brain cancer~~, glioma, astrocytomas, ependymal tumors, glioblastoma multiforme, and primitive neuroectodermal tumors.

8-11. (Canceled)

12. (New) The method of claim 1, wherein the at least one vaccination of DCs are primed.

13. (New) The method of claim 1, wherein the at least one vaccination of DCs are unprimed.

14. (New) The method of claim 1, wherein the COX-2 inhibitor is celecoxib, rofecoxib, valdecoxib, or meloxicam.